A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo Controlled, Single-Dose and Multiple-Ascending Dose Study of Orally Administered LY5625573 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein

Summary

The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them. Participation in the study will last up to approximately 7 weeks for Part A and 8.5 weeks for Parts B, C, D, and E. For each participant there will be one stay at the clinical research unit (CRU) lasting 5 nights for Part A, 18 nights for Parts B and C, and 17 nights for Parts D and E.

Eligibility

Age range

18–65 years

Sex

All

Healthy volunteers

Yes